{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:30:22Z","timestamp":1782271822738,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.medj.2025.100748","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T10:37:37Z","timestamp":1750415857000},"page":"100748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4)"],"prefix":"10.1016","volume":"6","author":[{"given":"Paul","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benita","family":"Ukkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph","family":"Caraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Narejos","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sady Armada","family":"Alpizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Francisco","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Grijalva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Orenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Fernsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongmi","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather Loryn","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100748_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/thoraxjnl-2019-213725","article-title":"Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18","volume":"75","author":"Pick","year":"2020","journal-title":"Thorax"},{"key":"10.1016\/j.medj.2025.100748_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41479-020-00074-3","article-title":"Etiology of community-acquired pneumonia in adults: a systematic review","volume":"12","author":"Shoar","year":"2020","journal-title":"Pneumonia"},{"key":"10.1016\/j.medj.2025.100748_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100748_bib4","article-title":"Prognostic factors for mortality in invasive pneumococcal disease in adult: a system review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2025.100748_bib5","unstructured":"Centers for Disease Control and Prevention (2021). Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2021. https:\/\/www.cdc.gov\/abcs\/downloads\/SPN_Surveillance_Report_2021.pdf."},{"key":"10.1016\/j.medj.2025.100748_bib6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14760584.2019.1582337","article-title":"Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States","volume":"18","author":"Wiese","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.medj.2025.100748_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3201\/eid2801.210734","article-title":"Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe","volume":"28","author":"Hanquet","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.medj.2025.100748_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/cid\/ciy872","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine among adults: A systematic review and meta-analysis","volume":"69","author":"Vadlamudi","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2025.100748_bib9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/21645515.2016.1277300","article-title":"Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world","volume":"13","author":"Cui","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.medj.2025.100748_bib10","unstructured":"Food and Drug Administration (2024). CAPVAXIVE. https:\/\/www.fda.gov\/vaccines-blood-biologics\/capvaxive."},{"key":"10.1016\/j.medj.2025.100748_bib11","unstructured":"HealthData.gov (2023). 2016-2021 Serotype Data for Invasive Pneumococcal Disease Cases by Age Group from Active Bacterial Core surveillance. https:\/\/healthdata.gov\/dataset\/2016-2021-Serotype-Data-for-Invasive-Pneumococcal-\/jq4r-xpxz\/about_data."},{"key":"10.1016\/j.medj.2025.100748_bib12","unstructured":"Gierke, R. (2024). Current Epidemiology of Pneumococcal Disease among Adults, United States. https:\/\/stacks.cdc.gov\/view\/cdc\/148683."},{"key":"10.1016\/j.medj.2025.100748_bib13","unstructured":"Food and Drug Administration (2021). PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. https:\/\/www.fda.gov\/media\/149987\/download."},{"key":"10.1016\/j.medj.2025.100748_bib14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.medj.2025.100748_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged \u226518 Years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2025.100748_bib16","unstructured":"Food and Drug Administration (2021). PNEUMOVAX 23 Prescribing Information. https:\/\/www.fda.gov\/media\/80547\/download."},{"key":"10.1016\/j.medj.2025.100748_bib17","unstructured":"European Medicines Agency (2021). Pneumovax 23 solution for injection in pre-filled syringe. https:\/\/www.medicines.org.uk\/emc\/product\/9692\/smpc#."},{"key":"10.1016\/j.medj.2025.100748_bib18","unstructured":"Food and Drug Administration. Vaccine Development 101. https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/vaccine-development-101."},{"key":"10.1016\/j.medj.2025.100748_bib19","doi-asserted-by":"crossref","first-page":"ofab605","DOI":"10.1093\/ofid\/ofab605","article-title":"Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18-49 years with or without risk factors for pneumococcal disease: a randomized phase 3 trial (PNEU-DAY)","volume":"9","author":"Hammitt","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.medj.2025.100748_bib20","unstructured":"Advisory Committee on Immunization Practices (2024). ACIP Recommendations. https:\/\/www.cdc.gov\/vaccines\/acip\/recommendations.html."},{"key":"10.1016\/j.medj.2025.100748_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal Vaccine for Adults Aged \u226519 Years, Recommendations of the Advisory Committee on Immunization Practices. United States, 2023.","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.medj.2025.100748_bib22","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.vaccine.2021.12.067","article-title":"Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged \u226550 years: A randomized phase 3 trial (PNEU-TRUE)","volume":"40","author":"Simon","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.medj.2025.100748_bib23","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.medj.2025.100748_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae220","article-title":"Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities","volume":"11","author":"Feemster","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.medj.2025.100748_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.4155\/bio-2020-0024","article-title":"Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.medj.2025.100748_bib26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/bio-2020-0023","article-title":"Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA","volume":"12","author":"Nolan","year":"2020","journal-title":"Bioanalysis"},{"key":"10.1016\/j.medj.2025.100748_bib27","unstructured":"ClinicalTrials.gov (2023). A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4). https:\/\/clinicaltrials.gov\/study\/NCT05464420."},{"key":"10.1016\/j.medj.2025.100748_bib28","unstructured":"EudraCT (2024). Clinical Trial Results: A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2022-000265-41\/results."},{"key":"10.1016\/j.medj.2025.100748_bib29","doi-asserted-by":"crossref","first-page":"27885","DOI":"10.1074\/jbc.M112.380451","article-title":"Biochemical, genetic, and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains: discovery of a new pneumococcal serotype","volume":"287","author":"Calix","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.medj.2025.100748_bib30","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhya Indian J. Stat."},{"key":"10.1016\/j.medj.2025.100748_bib31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.medj.2025.100748_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025001758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025001758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:01:04Z","timestamp":1762639264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025001758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666634025001758"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100748","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4)","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100748"}}